184 related articles for article (PubMed ID: 21987286)
1. Rechallenge with temozolomide in recurrent glioma.
Gaviani P; Silvani A; Lamperti E; Botturi A; Fariselli L; Simonetti G; Ferrari D; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S247-9. PubMed ID: 21987286
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
3. Rechallenge with temozolomide in patients with recurrent gliomas.
Wick A; Pascher C; Wick W; Jauch T; Weller M; Bogdahn U; Hau P
J Neurol; 2009 May; 256(5):734-41. PubMed ID: 19240962
[TBL] [Abstract][Full Text] [Related]
4. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
[TBL] [Abstract][Full Text] [Related]
5. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
6. Optimal role of temozolomide in the treatment of malignant gliomas.
Stupp R; van den Bent MJ; Hegi ME
Curr Neurol Neurosci Rep; 2005 May; 5(3):198-206. PubMed ID: 15865885
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
[TBL] [Abstract][Full Text] [Related]
8. New (alternative) temozolomide regimens for the treatment of glioma.
Wick W; Platten M; Weller M
Neuro Oncol; 2009 Feb; 11(1):69-79. PubMed ID: 18772354
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Wei W; Chen X; Ma X; Wang D; Guo Z
J Neurooncol; 2015 Nov; 125(2):339-49. PubMed ID: 26334318
[TBL] [Abstract][Full Text] [Related]
12. Current and future developments in the use of temozolomide for the treatment of brain tumours.
Stupp R; Gander M; Leyvraz S; Newlands E
Lancet Oncol; 2001 Sep; 2(9):552-60. PubMed ID: 11905710
[TBL] [Abstract][Full Text] [Related]
13. The use of temozolomide in recurrent malignant gliomas.
Gaya A; Rees J; Greenstein A; Stebbing J
Cancer Treat Rev; 2002 Apr; 28(2):115-20. PubMed ID: 12297119
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide dosing regimens for glioma patients.
Strik HM; Marosi C; Kaina B; Neyns B
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):286-93. PubMed ID: 22437507
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
[TBL] [Abstract][Full Text] [Related]
17. Impact of temozolomide on immune response during malignant glioma chemotherapy.
Sengupta S; Marrinan J; Frishman C; Sampath P
Clin Dev Immunol; 2012; 2012():831090. PubMed ID: 23133490
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
19. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Wang HW; Xu ZK; Song Y; Liu YG
Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
